Genetic Screen in a Preclinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities

Transcriptional co-analysis of TCGA patient samples to YAP1 and KRAS model tumors supports that these sarcoma subtypes lie along a spectrum of disease and adds guidance for further transcriptome-based refinement of sarcoma subtyping. This approach can be used to begin to understand pathways and mechanisms driving human sarcoma development, the relationship between sarcoma subtypes, and to identify and validate new therapeutic vulnerabilities for this aggressive and heterogeneous disease.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2024-08-23
DOI
https://doi.org/10.1158/1078-0432.ccr-24-1238
Citations
1
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.42

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Genetic Screen in a Preclinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities

Edmond F. O’Donnell, Janai R. Carr, Kathrin Plath, Thomas G. Graeber et al.
1 citations
Clinical Cancer Research
Sarcoma Diagnosis and Treatment
0.42
article

Genetic Screen in a Preclinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities

Edmond F. O’Donnell, Janai R. Carr, Kathrin Plath, Thomas G. Graeber, Kermit L. Carraway, Maria Muñoz, Justin Langerman, Julissa Suarez-Navarro, Jack Freeland, Steven W. Thorpe, R. Lor Randall, Morgan Darrow, Robert J. Canter, Owen N. Witte, Jessica Bergonio
article en
1 citations

Abstract

Transcriptional co-analysis of TCGA patient samples to YAP1 and KRAS model tumors supports that these sarcoma subtypes lie along a spectrum of disease and adds guidance for further transcriptome-based refinement of sarcoma subtyping. This approach can be used to begin to understand pathways and mechanisms driving human sarcoma development, the relationship between sarcoma subtypes, and to identify and validate new therapeutic vulnerabilities for this aggressive and heterogeneous disease.

Clinical Cancer ResearchVol. 30(21)
University of California, Los Angeles (US), Los Angeles Medical Center (US), Broad Center (US), University of California Davis Medical Center (US), University of California, Davis (US)
Howard Hughes Medical Institute, Burroughs Wellcome Fund, Doris Duke Charitable Foundation, W. M. Keck Foundation, Alan B. Slifka Foundation, National Institutes of Health, University of California, Davis, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Arthritis and Musculoskeletal and Skin Diseases
No poverty
Openalex Percentile: Top 34%
Sarcoma Diagnosis and Treatment
0.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.